The comparison is the facts. The Journal is the rest of it — what it's like to be dismissed for years, how to advocate for yourself, and how to recognize care that actually listens. Written by the women behind Selene.
Twenty-five years of records from nearly three million women found a 46% higher risk of type 2 diabetes with endometriosis — and the association was strongest in the women least likely to be screened for it.
More than 413,000 women, a fourfold higher risk of atherosclerotic heart disease — and it did not go away when researchers adjusted for weight. Why "lose weight and come back" is not a cardiovascular plan.
The first international consensus guidance on GLP-1s across contraception, conceiving, pregnancy and breastfeeding landed in late July. What it says, what it admits nobody knows, and the counselling you should be getting.
There is now an FDA-approved GLP-1 you swallow, and it has reached the telehealth dropdowns. What a tablet genuinely solves, what it doesn't, and why the format matters less than who is prescribing it.
The FDA's 503B bulks-list proposal shut to public comment on July 30. Nothing is final — but if your prescription is compounded, here are the five questions worth asking your provider this month.
Menopause already speeds bone loss — and a GLP-1 can quietly take muscle and bone with the weight. What the 2026 experts say, and the questions to ask before you start.
GLP-1 use among women with PMOS (PCOS) jumped more than sevenfold in four years. What's really driving it, what the evidence supports, and why semaglutide is still the better-studied choice.
Women with endometriosis were found to have lower GLP-1 levels where the disease lives. An intriguing clue — and a long way from a treatment. The early science, held carefully.
How a GLP-1 can quietly change the way your birth control works — and restart a fertility no one warned you about. The line from the paperwork that actually matters.
In 2026 researchers finally asked women with endometriosis what GLP-1s did for them. What the early evidence shows, what it can't yet — and why we keep our voice careful.
The weight that arrives in your forties isn't a discipline failure — it's a hormone story. What the newest research says about GLP-1s in perimenopause and menopause.
Why endometriosis takes so long to name, what a decade of "it's just a bad period" does to a person — and how to advocate for the care you deserve.
Ten years of diets that were supposed to fix you, the insulin piece no one mentions, and how to find a provider who treats PMOS (PCOS) as the metabolic condition it is.
These posts are general information from the women who write Selene. They are not medical advice, not recommendations, and not promises of any result — everyone's experience is different and results vary. Selene is editorial; we don't prescribe, sell, or dispense anything. GLP-1 medications are not FDA-approved specifically for PMOS (PCOS) and are not a treatment for endometriosis. Always talk to a licensed clinician about your own care.